![](https://static.wixstatic.com/media/fd8974_7936ec10ef2c47fd909044df86669d9c~mv2.png/v1/fill/w_53,h_35,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/fd8974_7936ec10ef2c47fd909044df86669d9c~mv2.png)
On August 10, 2018, the U.S. Food and Drug Administration made two major announcements related to contraception. First, it permitted marketing of Natural Cycles, a direct-to-consumer app for contraceptive use. Then it approved AnnoveraTM, a combined hormonal contraceptive ring.
Natural Cycles uses an algorithm to calculate the days of the month a woman is likely to be fertile based on daily basal body temperature readings and menstrual cycle information. This fertility-awareness based method is designed for use on mobile devices, among pre-menopausal women aged 18 and older.
Annovera is the first vaginal ring that provides pregnancy protection for a year. It is used for three weeks and then removed for one week, allowing for a withdrawal bleeding period. Annovera, which includes segesterone acetate and ethinyl estradiol, was developed by the Population Council and will be marketed by TherapeuticsMD in the United States.
![](https://static.wixstatic.com/media/fd8974_9c6316d94c764b9ea3d97a0a553b100b~mv2.jpg/v1/fill/w_138,h_131,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/fd8974_9c6316d94c764b9ea3d97a0a553b100b~mv2.jpg)